Monthly Archives: March 2015


Conditional Disease-free Survival after GIST Resection Improves Over Time

In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]

By |2019-04-08T09:46:50-04:00March 24th, 2015|News, Risk Assessment|

Novartis Gains Approval for Panobinostat

Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]

By |2019-04-08T09:34:28-04:00March 9th, 2015|Clinical Trials, Drug Treatment, News|
Go to Top